読み込み中
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
通常取引
$71.28
+$6.265 · +9.64%
日中の時刻はETです。市場データは遅延する場合があります。
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
日中レンジ
現在 $71.28
52週レンジ
現在 $71.28
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
34
割高
センチメント
49
まちまち
リスク
40
中程度のリスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
日中レンジ
現在 $71.28
52週レンジ
現在 $71.28
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 7.94億 USD | 4.77億 USD | 3.32億 USD | 1.69億 USD | 7841.1万 USD |
| 販売・一般管理 | 1.29億 USD | 9290.2万 USD | 6070万 USD | 3981万 USD | 2525.9万 USD |
| 営業費用 | 9.24億 USD | 5.7億 USD | 4.68億 USD | 2.32億 USD | 1.04億 USD |
| 受取利息 | 1.2億 USD | 1.1億 USD | 6290.7万 USD | 835.6万 USD | 34.4万 USD |
| 支払利息 | — | — | — | 2000 USD | 7000 USD |
| 減価償却費と償却費 | 2486万 USD | 1584.5万 USD | 1017.1万 USD | 945.3万 USD | 345.7万 USD |
| 営業利益 | −9.24億 USD | −5.7億 USD | −4.68億 USD | −2.32億 USD | −1.04億 USD |
| 純利益 | −7.67億 USD | −4.64億 USD | −4.02億 USD | −2.23億 USD | −1億 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2.79億0.01%2.3兆 USD0.03%$381.74+0.57%
iShares Russell 2000 ETFIWM2.26億0.29%776.97億 USD0.19%$278.99+0.51%
Vanguard Morningstar Small-Cap ETFVB2.02億0.11%1853億 USD0.03%$289.32+0.59%
State Street SPDR S&P Biotech ETFXBI1.34億1.33%101.08億 USD0.35%$154.38+3.41%
Vanguard Morningstar Small-Cap Growth ETFVBK1.16億0.25%447億 USD0.05%$344.3+1.09%
Vanguard Extended Market ETFVXF9279.29万0.10%954億 USD0.05%$234.81+0.72%
T. Rowe Capital Appreciation Equity ETFTCAF7837.57万0.86%90.1億 USD0.31%$43.535+0.78%
iShares Biotechnology ETFIBB7326.04万0.70%104.14億 USD0.44%$206.67+3.09%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFT. Rowe Capital Appreciation Equity ETFTCAFiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
